Clinilabs selected for phase II study

Friday, June 10, 2011 11:53 AM

New York-based CRO Clinilabs has been selected to conduct a phase II clinical research study of an investigational medication in patients with Major Depressive Disorder.

The trial will examine the effects of an investigational medication in treatment-resistant patients experiencing a current episode of depression.  This is Clinilabs’ fifth study in this therapeutic area.  Dr. Stephen Murray, Clinilabs’ Chief Medical Officer, said, “Major Depressive Disorder is a debilitating disease that carries with it both emotional and physical symptoms.  I am pleased to be involved in a clinical trial that is assessing a novel medication that may combat this condition.”

Enrollment for this study has begun. 

 

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

December 17

Medici Global says its Alzheimer's Facebook page demonstrates the need for more early detection trials

Analysts: Expect more equity purchases of CROs in 2013

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

January 2013

Parexel celebrates 30 years of change, growth
CRO's founder and chairman reflects on challenges of the past, present and future

Strategies for increasing patient diversity in trials
Sponsors look to improve racial, ethnic recruitment without going overseas

Already a subscriber?
Log in to your digital subscription.

Purchase the January issue.

Subscribe to The CenterWatch Monthly.

December 2012

Publicity, regulation tightening reins on use of KOLs
Debate rages over need to revamp how sponsors use, pay medical experts

Time may be right to makeover the investigator brochure
Size, complexity prevent critical document from being thoroughly read

Already a subscriber?
Log in to your digital subscription.

Purchase the December issue.

Subscribe to The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs